This trial is testing the safety and efficacy of combining ipatasertib with paclitaxel and carboplatin to treat ovarian cancer. Ipatasertib works by blocking some of the enzymes needed for cell growth, while paclitaxel and carboplatin work by killing or slowing the growth of tumor cells. The combination of these drugs may be more effective in treating ovarian cancer than paclitaxel and carboplatin alone.
3 Primary · 0 Secondary · Reporting Duration: Within the first cycle of neoadjuvant chemotherapy (1 cycle = 21 days)
Experimental Treatment
24 Total Participants · 1 Treatment Group
Primary Treatment: Ipatasertib · No Placebo Group · Phase 1
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: